ABOS News and Press, Acumen Pharmaceuticals Inc. From 06/13/23

Topline results for ACU193, the first clinical stage amyloid beta oligomer (A βO)-directed antibody, to provide deeper insight into candidate’s therapeutic potential for the treatment of early Alzheimer’s disease Phase 1 INTERCEPT-AD data investigating safety, pha...

2023-06-11 12:00:02 ET Driven by novel therapeutics from Biogen ( NASDAQ: BIIB )/ Eisai ( OTCPK:ESALF ) and Eli Lilly ( NYSE: LLY ), the Alzheimer’s disease market across eight major countries will reach $13.7B in 2030, the data analytics firm, GlobalData said las...

2023-05-14 02:22:08 ET Acumen Pharmaceuticals, Inc. (ABOS) Q1 2023 Earnings Conference Call May 09, 2023, 08:00 AM ET Company Participants Alex Braun - Head IR Daniel O'Connell - President and CEO Eric Siemers - Chief Medical Officer Matt Zuga - CFO and Chief...

2023-05-11 05:56:21 ET The U.S. Food and Drug Administration (FDA) approved the expanded use of H. Lundbeck ( OTCPK:HLBBF ) ( OTCPK:HLUBF ) and Otsuka's ( OTCPK:OTSKY ) ( OTCPK:OTSKF ) medicine Rexulti (brexpiprazole) to treat agitation associated with dementia due to Alzh...

2023-05-09 10:06:56 ET Acumen Pharmaceuticals press release ( NASDAQ: ABOS ): Q1 GAAP EPS of -$0.28 beats by $0.06 . For further details see: Acumen Pharmaceuticals GAAP EPS of -$0.28 beats by $0.06

Expect to report topline results from INTERCEPT-AD, a Phase 1 clinical trial of ACU193 in patients with early Alzheimer’s disease, in the third quarter of 2023 Cash, cash equivalents and marketable securities of $183.8 million as of March 31, 2023 expected to be sufficient to support c...

CHARLOTTESVILLE, Va. and CARMEL, Ind., May 04, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, ann...

2023-05-03 15:37:28 ET Eli Lilly ( NYSE: LLY ) added ~7% to reach a new 52-week high Wednesday after the company reported early Phase 3 data for its anti-amyloid agent donanemab in Alzheimer's disease, sparking sharp gains among rival drug developers. Notable gainers include...

CHARLOTTESVILLE, Va. and CARMEL, Ind., May 02, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligom...

Data describe induced pluripotent stem cell (iPSC)-derived excitatory neurons as a human model for assessing selectivity of drug binding to soluble amyloid beta oligomers in Alzheimer’s disease Results provide evidence that oligomer size may influence neuronal binding and detecti...